The wire services screwed up this morning. These are Ligand numbers
Viking Therapeutics sees 2024 adjusted EPS $4.25-$4.75 vs. $4.06 in 2023 07:09 VKTX Still sees 2024 revenue $130M-$142M vs. $131.3M in 2023. Show Related Items >> Viking Therapeutics reports Q4 core adjusted EPS $1.05, consensus (28c) 07:07 VKTX Reports Q4 revenue $28.1M vs. $26.8M last year. "2023 was a transformative year for Ligand, both operationally and financially. We refocused the company to be a lean-infrastructure, high-margin business," said Todd Davis, CEO. "We enhanced our deal making capabilities with the strengthening of our senior team and opening of a Boston office. These initiatives will help us execute on a larger scale and continue to expand our portfolio through a focus on life science royalty opportunities. We are now well positioned and resourced to close on multiple new investments. We also saw important clinical and regulatory events across our existing partnered assets and expect this momentum will continue in 2024 and beyond."
The data provided so far shows VK2735 to be both more efficacious and more tolerable than tirzepatide. It was a home run especially on tolerability given the aggressive dosing/titration. Comments by analysts in the conference call included: "Looks more potent than Zepbound" "Stellar" and "Pristine profile".
I will comment in more detail later once I see the transcript, listen to the CC again but it sure looks "Best in Class" to me right now. :-)
News 
Market Data 
Discover 
